Jurisdictional differences in opioid use, other licit and illicit drug use, and harms associated with substance use among people who tamper with pharmaceutical opioids

Drug and Alcohol Review

Volumn 34, Issue 6, 2015, Pages 611-622

  Peacock, Amy ^a   Bruno, Raimondo ^a   Cama, Elena ^b   Kihas, Ivana ^b   Larance, Briony ^b   Lintzeris, Nick ^c   Hordern, Antonia ^b   White, Nancy ^d   Ali, Robert ^d   Degenhardt, Louisa ^b  

^a UNIVERSITY OF TASMANIA   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Heroin; Injecting drug use; Non adherence; Pharmaceutical opioid; Prescription drug misuse

Indexed keywords

NARCOTIC ANALGESIC AGENT; OXYCODONE;

ADULT; ALCOHOLISM; DRUG MISUSE; FEMALE; HUMAN; INTERVIEW; MALE; MORPHINE DEPENDENCE; NEW SOUTH WALES; OPIOID-RELATED DISORDERS; PAIN; PROCEDURES; SOUTH AUSTRALIA; STATISTICS AND NUMERICAL DATA; SUBSTANCE ABUSE; TASMANIA;

ADULT; ALCOHOLISM; ANALGESICS, OPIOID; FEMALE; HUMANS; INTERVIEWS AS TOPIC; MALE; METHODS; MORPHINE DEPENDENCE; NEW SOUTH WALES; OPIOID-RELATED DISORDERS; OXYCODONE; PAIN; PRESCRIPTION DRUG MISUSE; SOUTH AUSTRALIA; SUBSTANCE ABUSE, INTRAVENOUS; TASMANIA;

EID: 84945464777     PISSN: 09595236     EISSN: 14653362     Source Type: Journal    
DOI: 10.1111/dar.12279     Document Type: Article

References (28)

1. Degenhardt L, Charlson F, Mathers B, etal. The global epidemiology and burden of opioid dependence: results from the Global Burden of Disease 2010 study. Addiction 2014;109:1320-1333.
2. Degenhardt L, Hall W. Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet 2012;379:55-70.
3. Blanch B, Pearson SA, Haber PS. An overview of the patterns of prescription opioid use, costs and related harms in Australia. Br J Clin Pharmacol 2014;78:1159-1166.
4. Australian Institute of Health and Welfare. 2010 National Drug Strategy Household Survey report. Canberra: Australian Institute of Health and Welfare, 2011.
5. Stafford J, Burns L. Australia Drug Trends 2013: Findings from the Illicit Drug Reporting System (IDRS). Sydney: NDARC, University of New South Wales, 2014.
6. Roxburgh A, Bruno R, Larance B, Burns L. Prescription of opioid analgesics and related harms in Australia. Med J Aust 2011;195:280-284.
7. Rintoul AC, Dobbin MD, Drummer OH, Ozanne-Smith J. Increasing deaths involving oxycodone, Victoria, Australia, 2000-09. Inj Prev 2011;17:254-259.
8. Darke S, Duflou J, Torok M. Toxicology and characteristics of fatal oxycodone toxicity cases in New South Wales, Australia 1999-2008. J Forensic Sci 2011;56:690-693.
9. Australian Crime Commission. 2012-2013 Illicit Drug Report Data. ACT, 2014.
10. National Drug and Alcohol Research Centre. A Review of Opioid Prescribing in Tasmania: A Blueprint for the Future. Sydney: NDARC, University of New South Wales, 2012.
11. Degenhardt L, Black E, Breen C, Bruno R. Trends in morphine prescriptions, illicit morphine use and associated harms among regular injecting drug users in Australia. Drug Alcohol Rev 2006;25:403-412.
12. Berbatis CG, Sunderland VB, Bulsara M, Lintzeris N. Trends in licit opioid use in Australia, 1984-1998: Comparative analysis of international and jurisdictional data. Med J Aust 2000;173:524-527.
13. Degenhardt L, Larance B, Bruno R, Lintzeris N, Ali R, Farrell M. Evaluating the potential impact of a reformulated version of oxycodone upon tampering, non-adherence and diversion of opioids: the National Opioid Medications Abuse Deterrence (NOMAD) study protocol. Addiction 2015;110:226-237.
14. Kessler RC, Üstün TB. The world mental health (WMH) survey initiative version of the World Health Organization (WHO) Composite International Diagnostic Interview (CIDI). Int J Methods Psychiatr Res 2004;13:93-121.
15. Tan G, Jensen MP, Thornby JI, Shanti BF. Validation of the Brief Pain Inventory for chronic nonmalignant pain. J Pain 2004;5:133-137.
16. Kroenke K, Spitzer RL, Williams JB, Lowe B. The Patient Health Questionnaire Somatic, Anxiety, and Depressive Symptom Scales: a systematic review. Gen Hosp Psychiatry 2010;32:345-359.
17. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001;16:606-613.
18. Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 2006;166:1092-1097.
19. Prins A, Ouimette P, Kimerling R, etal. The primary care PTSD screen (PC-PTSD): development and operating characteristics. Int J Psychiatry Clin Pract 2004;9:9-14.
20. Babor TF, Higgins-Biddle JC, Saunders JB, Monteiro MG. The Alcohol Use Disorders identification Test. Guidelines for Use in Primary Care, 2nd edn. 2001. Available at: http://www.talkingalcohol.com.au/files/pdfs/WHO_audit.pdf.
21. Gossop M, Darke S, Griffiths P, etal. The Severity of Dependence Scale (SDS): psychometric properties of the SDS in English and Australian samples of heroin, cocaine and amphetamine users. Addiction 1995;90:607-614.
22. Topp L, Mattick RP. Choosing a cut-off on the Severity of Dependence Scale (SDS) for amphetamine users. Addiction 1997;92:839-845.
23. Dwyer R, Topp L, Maher L, etal. Prevalences and correlates of non-viral injecting-related injuries and diseases in a convenience sample of Australian injecting drug users. Drug Alcohol Depend 2009;100:9-16.
24. Australian Institute of Health and Welfare. National Opioid Pharmacotherapy Statistics Annual Data (NOPSAD). 2014.
25. NSW Ministry of Health. New South Wales Opioid Treatment Program: clinical guidelines for methadone and buprenorphine treatment of opioid dependence: NSW Ministry of Health, 2006.
26. South Australia Health. Policy for non-supervised dosing of methadone and buprenorphine in drug treatment programs: South Australia Health, 2012.
27. Department of Health and Human Services. Tasmanian Opioid Pharmacotherapy Program, Policy and Clinical Practice Standards. Hobart: Tasmanian Government, 2012.
28. Shand FL, Campbell G, Hall W, Lintzeris N, Cohen M, Degenhardt L. Real-time monitoring of Schedule 8 medicines in Australia: evaluation is essential. Med J Aust 2013;198:80-81.